ReviewDrugs2013
Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.
Review in Drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 50 citations in OpenAlex.
- A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy.International journal of molecular sciences · 2025Review
- Research progress in targeted therapy and immunotherapy for gastric cancer.Chinese medical journal · 2022Review
- State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer.Biologics : targets & therapy · 2021Review
- Personalized medicine in colorectal cancer.Gastroenterology and hepatology from bed to bench · 2020Review
- Plant/Bacterial Virus-Based Drug Discovery, Drug Delivery, and Therapeutics.Pharmaceutics · 2019Review
- Targeted and novel therapy in advanced gastric cancer.Experimental hematology & oncology · 2019Review
- Immuno-PET imaging of VEGFR-2 expression in prostate cancer withAmerican journal of cancer research · 2019Article
- Quantitative Analysis of HER2 Amplification by Droplet Digital PCR in the Follow-Up of Gastric Cancer Patients Being Treated with Trastuzumab after Surgery.Gastroenterology research and practice · 2019Article
- Article
- HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.Oncotarget · 2016Review
- Review
- PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Article
- Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer.OncoTargets and therapy · 2016Review
- Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features.World journal of gastrointestinal oncology · 2015Review
- Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update.World journal of gastroenterology · 2015Review
- Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.The oncologist · 2015Review
- Computational systems biology approaches to anti-angiogenic cancer therapeutics.Drug discovery today · 2015Review
- Obesity-related known and candidate SNP markers can significantly change affinity of TATA-binding protein for human gene promoters.BMC genomics · 2015Article
- Clinical utility of ramucirumab in advanced gastric cancer.Biologics : targets & therapy · 2015Review
- Clinical advances in the development of novel VEGFR2 inhibitors.Annals of translational medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although antiangiogenic treatments have produced milestone advances in the treatment of several diseases, and have significantly extended the median survival of cancer patients, these agents share some weaknesses, including a limited impact on the overall cure rate, a fleeting effect because of redundant pathways or early appearance of resistance mechanisms, and the lack of predictive factors for treatment selection. Recent data suggest that antibodies targeting the vascular endothelial growth factor axis exert their activity through the inhibition of vascular endothelial growth factor receptor-2 phosphorylation, which has a pivotal role in the neoangiogenic process. Ramucirumab, a fully humanized monoclonal antibody specifically directed against the extracellular domain of the receptor, administered intravenously every 2 or 3 weeks, is emerging as a novel antiangiogenic opportunity. Starting with preclinical data and early clinical results, this concise review focuses on the development of the novel compound across multiple cancers (including gastrointestinal malignancies, breast cancer, lung carcinoma, and genitourinary tumors), and presents available data from randomized phase II and phase III trials. REGARD was the first phase III study to report on the efficacy of single-agent ramucirumab in patients with advanced cancer. Many other ongoing phase III trials are testing the efficacy of this interesting antiangiogenic compound as a single agent or in combination with chemotherapy in different cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.